No Data
Wedbush Reiterates Outperform on Inozyme Pharma, Maintains $15 Price Target
Inozyme Pharma Analyst Ratings
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16
Stifel analyst Dae Gon Ha maintains $Inozyme Pharma(INZY.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 46.0% and a total
This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday